Cationic liposomes have been shown to potentiate markedly the ability of plasmid DNA to activate innate immune responses. We reasoned therefore that liposome-DNA complexes (LDC) could be used to produce more effective plasmid DNA vaccines for cancer. To test this hypothesis, tumor-bearing mice were vaccinated with conventional plasmid DNA vaccines or with LDC vaccines encoding model tumor antigens and CD8 þ T-cell responses and antitumor activity were assessed. We found that although plasmid DNA vaccines generated large increases in antigen-specific CD8 þ T cells, they failed to elicit significant antitumor immunity. In contrast, LDC vaccines elicited large numbers of antigen-specific CD8 þ T cells and also generated significant antitumor activity against established tumors. The antitumor activity elicited by immunization with LDC vaccines was mediated primarily by CD8 þ T cells. Studies of the interaction of LDC with antigen-presenting cells found that LDC triggered dendritic cell production of interleukin-12 and interferon (IFN)-g production by natural killer cells in vivo. Activation by LDC was also accompanied by upregulation of costimulatory molecule expression. These findings suggest that by concurrently activating strong systemic innate immune responses and generating cytotoxic T-lymphocyte responses, LDC may be used to increase the effectiveness of therapeutic plasmid DNA vaccination for cancer.
Introduction
Cancer vaccines continue to hold a great promise because of their potential to not only control established tumors but to also prevent tumor metastases. [1] [2] [3] [4] [5] Impressive clinical responses to cancer vaccines have been observed in a few recent human clinical trials, although the overall track record for cancer vaccines is less impressive. [6] [7] [8] It is apparent therefore that a number of hurdles remain and there is still a strong need for improvements in tumor vaccine design before they realize their full potential. 8, 9 Improvements in tumor vaccine delivery systems are an important component of current research efforts. Previous tumor vaccine strategies have included immunization with whole tumor cell or tumor lysate vaccines, peptide vaccines, dendritic cell (DC) vaccines, viralvectored vaccines and plasmid DNA vaccines. 5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Plasmid DNA vaccines are attractive because they are relatively easy to engineer and produce and are safe to administer to humans. 1, 5, [21] [22] [23] [24] A number of studies have reported the use of plasmid DNA-based vaccines for eliciting antitumor immunity in mice. [25] [26] [27] [28] [29] [30] However, induction of therapeutic antitumor activity, especially against tumor metastases to the lungs, has been more difficult to achieve using DNA vaccines. In some cases, co-administration of high doses of recombinant cytokines can increase the efficacy of plasmid DNA vaccination. 29, 31 However, in human clinical trials, plasmid DNA vaccines have generally failed to elicit significant antitumor activity in patients with established tumors. 8, 32, 33 Thus, despite the theoretical advantages of plasmid DNA vaccination, there are still significant unresolved issues in the application of plasmid DNA vaccination for therapeutic induction of antitumor immunity.
The current generation of plasmid DNA-based cancer vaccines may fail to elicit effective antitumor immunity because they do not trigger sufficient systemic activation of innate immunity. One solution to this problem is to couple vaccination with systemic immunotherapy. For example, systemic administration of interleukin (IL)-2 and IL-12 significantly improved the efficacy of DNA vaccines in mouse tumor models. 29 However, an alternative approach that would avoid the need to administer recombinant cytokines would be to modify the plasmid DNA delivery system to achieve a greater activation of innate immunity during vaccination. Complexing cationic liposomes to the plasmid DNA offers a relatively simple means of accomplishing this, as our group and others have shown that liposome-DNA complexes (LDC) are extremely potent activators of innate immunity. [34] [35] [36] For example, systemic administration of LDC triggers strong activation of innate immune responses and release of high concentrations of key T helper type 1 (Th1)-biasing cytokines, including IL-12, interferon (IFN)-g and type I IFNs. In addition, systemic administration of LDC can elicit potent antitumor activity. 34, [36] [37] [38] Therefore, we hypothesized that LDC could be used effectively as a DNA vaccine platform to enhance the generation of therapeutic antitumor immunity through the combined activation of systemic innate and adaptive immune responses.
To address this hypothesis, we immunized tumorbearing mice with conventional plasmid DNA vaccines or with LDC vaccines and assessed antigen-specific CD8 þ T-cell responses, generation of antitumor activity and activation of antigen-presenting cells (APCs). We found that immunization with LDC administered intravenously (i.v.), even using very low doses of plasmid DNA, induced superior T-cell responses and antitumor immunity compared to other methods of plasmid DNA immunization. In particular, LDC vaccination elicited large numbers of functionally active, and tumorspecific CD8 þ T cells infiltrating tumor tissues. Administration of LDC also triggered in vivo activation of DCs, macrophages and natural killer (NK) cells, whereas vaccination with plasmid DNA alone did not. We conclude therefore that LDC cancer vaccines administered systemically may be a uniquely effective means of generating therapeutic antitumor immunity.
Materials and methods

Plasmids
The ovalbumin gene was a kind gift of Dr Micheal Bevan, University of Washington. The ovalbumin gene was subcloned into an expression vector containing the tPA leader sequence for secretion, along with a cytomegalovirus (CMV) promoter, and the bovine growth hormone polyadenylation sequence (a kind gift of Dr Keith Rushlow, Heska Corp, Ft Collins, CO). A b-gal plasmid construct containing the b-gal gene under the transcriptional control of the human CMV immediate-early promoter and the SV-40 polyadenylation sequence was used, as reported previously. 39 Plasmid DNA was prepared by the modified alkaline lysis procedure, followed by polyethylene glycol precipitation, as described previously. 40 Preparation of LDC Sterile 10 mM solutions of the cationic liposome DOTIM octadecenoyloxy(ethyl-2-heptadecenyl-3-hydroxyethyl) imidazolinium chloride and cholesterol were prepared in a 1:1 molar ratio as described previously, except that the liposomes were extruded through a final filter diameter of 200 nm rather than 100 nm. 41 LDC were formed just before injection by gently mixing cationic liposomes with plasmid DNA at a ratio of 16 nmol lipid per 1 mg DNA in 5% dextrose in water at room temperature. The final plasmid DNA concentration in the complexes was 100 mg DNA per ml.
Tumor cell lines
The CT26 tumor line and the b-gal stable transfectant of CT-26 (CL-25) were a kind gift of Dr Nicholas Restifo (National Cancer Institute, Bethesda, MD). The B16.F10 cell line was obtained from Dr Isiah Fidler (MD Anderson, Houston, TX) and the B16-ova stable transfectant was a kind gift from Dr Richard Duke (University of Colorado Health Sciences Center, Denver, CO). Cells were maintained in modified Eagle's complete medium with 5% fetal bovine serum (FBS) with streptomycin and penicillin (Sigma Chemical Co, St Louis, MO). Cells were periodically treated with ciprofloxacin (10 mg/ml) to assure mycoplasma-free conditions.
Animals and tumor inoculations
Experiments with CL25 tumors were carried out in female BALB/c mice, 8-12 weeks of age, obtained from HarlanSprague-Dawley Laboratories (Indianapolis, IN) and experiments with B16-ova tumors were carried out in female C57Bl6 mice obtained from the same vendor. Cutaneous tumors were established by intradermal (i.d.) injection of 2 Â 10 5 tumor cells. Treatments were initiated 7 days post-tumor inoculation (B16-ova tumors) or 12 days post-tumor inoculation (CL25 tumors), at a time when tumor nodules were palpable. Tumor diameters were measured using calipers every 2-3 days once treatments were initiated. Mice were killed once the tumor diameter reached 1.5 cm. Pulmonary metastases were established by i.v. injection of 2.5 Â 10 5 tumor cells and treatments were started 3 days later. The lung tumor burden was quantitated by counting the number of lung metastases as described previously. 42 Animal protocols for these experiments were approved by the Institutional Animal Care and Use Committees at the National Jewish Medical and Research Center and at Colorado State University.
DNA vaccinations
Mice were immunized by the i.d., intramuscular (i.m.) or i.v. routes with plasmid DNA alone or with plasmid DNA formulated as LDC. For immunization with plasmid DNA alone, mice received 50 mg plasmid DNA dissolved in 200 ml saline (i.m. immunization) or in 100 ml saline (i.d. immunization). For i.m. immunization, equal amounts of DNA were injected bilaterally in the tibialis muscles of anesthetized mice. For i.d. immunization, mice were injected in the skin of the base of the tail, using a no. 27 needle. Mice received two immunizations, administered 7 days apart. For i.v. immunization with LDC, mice received 5 mg plasmid DNA in 50 ml of LDC, administered via the lateral tail vein, followed by a second immunization 7 days later. For i.d. and i.m. immunization with Liposome-DNA vaccines for cancer L U'Ren et al LDC, mice were injected with 50 mg total DNA in LDC in a total volume of 200 ml 5% dextrose in water, in the skin of the tail base or bilateral tibialis muscles, respectively.
Cytotoxicity assay
Cytotoxic T-lymphocyte (CTL) responses to vaccination were quantitated using a 51 Cr-release assay, as described previously. 43 Briefly, spleen cells were harvested and restimulated in vitro in 24-well plates by pulsing with 1 mM ova8 (SIINFEKL) peptide for 5 days. The cell culture medium was supplemented with 1% concanavalin-Astimulated rat spleen cell supernatants beginning on day 2 in culture. At 5 days, the cells were harvested and assayed at decreasing effector-to-target ratios for their ability to lyse ova8 peptide-pulsed major histocompatibility complex (MHC)-matched, 51 Cr-pulsed EL-4 target cells. Controls included incubation of spleen effector cells with 51 Cr -labeled EL-4 cells that were not pulsed with peptide. Target EL-4 cells were pulsed for 1 h with 51 Cr and then 5 Â 10 3 -labeled target cells were added to each well of a Linbro plate, followed by the addition of effector cells, beginning at an effector-to-target ratio of 50:1. After 4 h incubation at 371C, supernatants were harvested and assayed for release of 51 Cr by automated gamma counter. The percentage-specific lysis was calculated using the following formula: observed Cr minus spontaneous Cr release, divided by maximum Cr release minus spontaneous Cr release. The mean specific lysis detected in 4-5 animals per treatment group was plotted.
Flow cytometry
Directly conjugated antibodies used for flow cytometric analysis were purchased either from Pharmingen (San Diego, CA) or from eBiosciences (San Diego, CA). The following antibodies were used: anti-CD8a (APC; clone 53.6.7), anti-CD4 (APC; clone RM4-5), anti-CD44 (fluorescein isothicynate (FITC): clone IM7), anti-CD62L (phycoerythrin (PE)/Cy5; clone Mel-14), anti-CD69 (PE/ cy7; clone H1.2F3), anti-I-A/I-E (MHC II, biotin or PE; clone M5/114.15.2), followed by either SA-pe/cy5 or SA-Alexa-350 (Molecular Probes Inc., Eugene, OR), antiCD11b (PE-Cy5 or APC-Cy7; clone M1/70), anti-CD11c (PE or APC; clone N418), anti-Gr-1 (PeCy7; clone RB6-8C5), B220 (APC-Cy7; clone RA3-6B2), anti-NK1.1-biotin (clone PK 136) or anti-CD3 (APC-Cy7; clone 145-2C11). Nonspecific binding of antibodies was blocked by pre-incubation of cells in normal mouse serum with 40% supernatant from rat anti-FcRIII hybridoma 24.G2, plus 0.2 mg/ml human immunoglobulin (Ig)G. Antibodies were diluted in fluorescence-activated cell sorting (FACS) buffer (phosphate-buffered saline with 2% FBS and 0.1% sodium azide) for staining. Staining (except for tetramers) was carried out at 41C for 20 min, followed by washing in FACS buffer. In most cases, cells were fixed in 1% paraformaldehyde for 30 min and stored in FACS buffer at 41C before analysis. Flow cytometry was performed using either a BD FACSCalibur cytometer (BD, Pleasanton, CA) for four-color analysis or a Cyan MLE cytometer (Dako-Cytomation, Ft Collins, CO) for six-to seven-color analysis. Gates for analysis of CD8 þ T-cell responses were drawn to include live lymphocytes, based on forward and side-scatter characteristics of spleen cells, whereas larger gates were selected for the analysis of APCs. For most experiments, the total CD8 þ cell population was analyzed to determine the percentage of tetramer-positive events as a percentage of all CD8 þ T cells. A minimum of 200 000 total events were collected for tetramer experiments. Data analysis was carried out using either CellQuest software or Summit Software.
MHC-peptide tetramer analysis H-2K
b MHC class I tetramers containing the ova8 peptide (SIINFEKL) were produced as described previously. 44 The CD8 þ T-cell response to DNA vaccination against ovalbumin was assessed in C57Bl6 mice with established cutaneous B16-ova tumors. Single-cell suspensions lymph node and tumor tissues were prepared by pressing through nylon mesh, followed by lysis of erythrocytes using ammonium chloride. Spleen mononuclear cells were prepared by dissociation of spleens, followed by NH 4 Cl lysis of erythrocytes. Tumor tissues were weighed before preparation of single-cell suspensions and cell numbers after dissociation were determined by Coulter counter. For tetramer staining, single-cell suspensions (approximately 5 Â 10 5 to 1 Â 10 6 cells/well of 96-well plates) were incubated for 1.5 h at 371C in 100 ml tissue culture medium with the appropriate tetramer concentration, as determined by staining of positive control ova-TCR Tg OT-1 cells. 43 After incubation with tetramers, cells were incubated with anti-CD8-APC (clone 53-6.7), anti-CD44 FITC (clone IM7; both from Pharmingen, San Diego, CA) and with biotinylated anti-I-A b antibody (clone Y3P), followed by incubation with streptavidin PE-Cy5 conjugate (Pharmingen). For tetramer analysis, at least 200 000-500 000 total events per sample were collected. Total CD8 þ T cells were gated and then analyzed for tetramer binding and CD44 expression. I-A b þ cells were excluded from the analysis to reduce nonspecific staining. The total number of tetramer-positive cells in tumor, spleen and lymph node tissues was determined by counting the total number of live mononuclear cells analyzed and multiplying by the percentage of tetramer-positive cells. In the case of tumor tissues, the number of ova8-specific CD8 þ T cells was also expressed as cells per gram tumor weight in order to adjust for variability in tumor sizes.
Tracking distribution of labeled LDC
Fluorescently labeled liposomes were used to track uptake of LDC in the spleen following i.v. injection. Liposomes were labeled by incorporating BODIPY-labeled cholesterol (Molecular Probes, Eugene, OR) during preparation of the liposomes, as described previously. 45 At various time points after i.v. injection of labeled LDC, spleens were collected, digested for 20 min in 1 mg/ml collagenase, then single-cell suspensions were prepared and immunostained with panels of antibodies specific for APCs and lymphocytes. Cells were analyzed using a Cyan MLE multicolor flow cytometer, with data analysis carried out using Summit software. The mean percentage of BODIPY þ cells of different cell types was determined for individual mice and the mean value for groups of 3-4 mice per group was determined. Controls included untreated mice and mice injected with unlabeled LDC. For activation of APCs, the mean percentage of macrophages or DCs expressing CD86 was determined by comparison to untreated control mice (3-4 animals per treatment group).
Intracellular cytokine staining
Spleen cells were immunostained for the detection of intracellular cytokines as described previously. 46 Briefly, cells were collected at various time points after injection of DNA or LDC and then placed in FACS buffer in the presence of 10 mg/ml monensin. After 4-5 h incubation, the cells were immunostained for detection of cell surface antigens, then fixed and permeabilized and stained for intracellular cytokines. Antibodies used for intracellular cytokine staining included anti-mouse IL-12 (PE; clone C17.8) and anti-mouse IFN-g (PE; clone XMG1.2), both from eBiosciences. For each experiment, controls included cells from untreated mice and conjugated monoclonal antibody matched to the isotype of the cytokine antibodies. The percentage of cells expressing a given cytokine were determined for each group of mice and the mean (7s.e.) of the cytokine-positive populations was calculated.
Cytokine release assay Antigen-specific generation of IFN-g by CD8 þ T cells was assessed by culturing single-cell suspensions of spleen cells from ova DNA-vaccinated mice overnight at a concentration of 2 Â 10 6 cells/ml in complete medium in the presence or absence of 1 mM ova8 peptide. Supernatants were collected 18 h later and assayed for the release of IFN-g, using a commercial ELISA assay (R&D Systems, Minneapolis, MN). Controls included spleen cells from non-immunized mice and spleen cells from immunized mice incubated without peptide.
Antibody depletion of effector cells
Antibody depletion was initiated 24 h before vaccination and was repeated once weekly. CD4 þ T cells were depleted by intraperitoneal administration of 50 mg purified rat-anti mouse CD4 IgG (clone GK1.5), CD8 þ T cells were depleted using 50 mg of rat anti-mouse CD8 IgG (clone 2.43) and NK cells were depleted using 50 mg purified rabbit anti-asialo GM1 antiserum (Wako Bioproducts, Richmond, VA). The doses of depleting antibodies used for inducing efficient depletion of selected cell populations were determined by in vivo titration and depletion was confirmed by flow cytometric analysis (data not shown).
Statistical analysis
In experiments with multiple groups of mice, statistical differences between treatment groups were compared using analysis of variance (ANOVA) and Tukey's multiple means comparisons test. For comparisons between two treatment groups, Student's t-test was used. Survival curves were generated using Kaplan-Meier analysis, and statistical significance was determined using w 2 analysis. Statistical analyses were carried out using GraphPad Prism software (San Diego, CA). A P-value o0.05 was considered significant for these analyses.
Results
Immunization with plasmid DNA or with LDC vaccines generates antigen-specific CD8 þ T-cell responses in spleen and tumor tissues Previous studies have established that i.d. and i.m. administration of plasmid DNA is an effective means of generating CD8
þ T-cell responses against tumor antigens. 25, 26 However, the effectiveness of LDC-based vaccines for eliciting CD8 þ T-cell responses has not been reported previously. For these experiments, major histocompatibility complex class I tetramers were used to quantitate and compare CD8 þ T-cell responses to DNA vaccination in tumor-bearing mice. The model antigen ovalbumin was used in these studies as the immunological reagents necessary for the analysis of ova-specific T cells were readily available. We also used the B16 melanoma cell line transfected with the ovalbumin gene (B16-ova) to facilitate tracking of tumor-specific T-cell responses in vivo.
In the first experiments, we compared the magnitude of CD8 þ T-cell responses to vaccination with plasmid DNA when the DNA was administered by different routes and formulated either as 'naked' plasmid DNA or complexed to cationic liposomes (LDC vaccines). Mice with established B16-ova tumors were immunized twice with DNA encoding ovalbumin and then spleen and tumor tissues were analyzed for the presence of ova-specific CD8 þ T cells a week after the last immunization using Kb-ova8 tetramers and flow cytometry. Following i.d. or i.m. immunization with 50 mg plasmid DNA, there was a significant expansion in the number of ova-specific CD8 þ T cells in spleen tissues (data not shown) and in tumor tissues ( Figure 1 ). The increase in ova-specific CD8 þ T cells was particularly pronounced in tumor tissues of mice immunized i.m. with plasmid DNA, where approximately 20% of all tumor-infiltrating CD8 þ T cells were ova specific (Figure 1 ). In mice immunized with 5 mg of plasmid DNA formulated as LDC and administered i.v., there was also a significant (Po0.05) increase in ovaspecific CD8 þ T cells in both spleen (not shown) and tumor tissues (Figure 1b) . Also, in tumor tissues virtually all the CD8 þ T cells expressed high levels of CD44, consistent with a memory effector cell phenotype (data not shown). Therefore, both conventional plasmid DNA immunization and immunization with LDC elicited significant increases in the numbers of antigen-specific CD8 þ T cells in tumor-bearing mice. Notably, i.v. immunization with LDC was much more efficient than i.m. or i.d. immunization with plasmid DNA only, as only a tenth of the dose of plasmid DNA was utilized for LDC immunization. As a control, mice treated by i.v. administration of LDC containing non-coding plasmid Immunization with LDC elicits CTL with greater functional activity than plasmid DNA immunization The preceding experiments indicated that DNA immunization using either plasmid DNA or LDC could elicit significant increases in antigen-specific CD8 þ T cells. However, the functionality of T cells elicited by vaccination is also important in the generation of antitumor immunity. Therefore, we compared the cytotoxic activity of CD8 þ T cells elicited by the different DNA vaccines. Spleen cells were collected from tumor-bearing mice (four C57Bl6 mice per group) immunized twice with ova DNA by i.d. or i.m. administration of plasmid DNA or i.v administration of LDC. Control groups included untreated tumor-bearing mice and tumor-bearing mice treated by i.v. administration of LDC prepared with noncoding DNA. Spleen cells were re-stimulated in vitro for 5 days with 1 mM ova8 peptide and then assessed for their ability to lyse 15 Cr-labeled EL-4 target cells pulsed with the ova8 peptide. We found that spleen cells from mice Liposome-DNA vaccines for cancer L U'Ren et al immunized with LDC exhibited significantly greater specific cytotoxic activity than spleen cells from control mice (Po0.01) (Figure 2 ). In addition, mice immunized with ova LDC also developed significantly greater cytolytic activity than mice immunized i.d. or i.m. with ova plasmid DNA (Po0.01). Mice treated by i.v. administration of LDC prepared with non-coding DNA, however, did not develop significantly greater CTL activity when compared to ova-LDC immunized mice (Po0.05). In addition, spleen cells from mice immunized with ova LDC released greater amounts of IFN-g in response to restimulation with ova8 peptide than spleen cells from mice immunized with ova plasmid DNA (data not shown). These data indicated therefore that immunization with LDC not only elicited large numbers of antigen-specific CD8 þ T cells but that the T cells that were generated were also functionally more active.
Therapeutic immunization with LDC vaccines controls tumor growth in cutaneous and lung tumor models
Experiments were conducted next to assess the ability of DNA vaccines to elicit therapeutic antitumor immunity in mice with established cutaneous tumors, using two wellstudied tumor models. In the first experiments, B16-ova tumors were established in the skin of C57Bl6 mice and immunizations were not begun until day 7 after tumor inoculation, at which point the tumors were palpable (2-3 mm diameter). Treatment groups (five mice per group) included untreated control mice, mice immunized i.d. with 50 mg ova DNA, mice immunized i.m. with 50 mg ova DNA, mice immunized i.v. with 5 mg ova LDC and mice immunized i.v. with 5 mg empty vector LDC. This last treatment group was included to control for the antitumor activity elicited by i.v. administration of empty vector LDC. 34 Mice were each immunized twice, 1 week apart, and tumor size was determined every 2-3 days and mice were killed when tumor diameter exceeded 1.5 cm.
We found that immunization with ova LDC significantly inhibited tumor growth (Po0.001) compared to untreated control mice or to mice immunized with ova plasmid DNA (Figure 3) . Immunization with ova LDC also elicited significantly greater inhibition of tumor growth than i.v. administration of empty vector LDC (Po0.01). We also observed that i.d. or i.m. immunization with ova LDC did not elicit detectable antitumor activity, nor did i.v. administration of ova plasmid DNA alone (data not shown). These results indicated that i.v. immunization with LDC was uniquely effective in eliciting therapeutic antitumor activity, compared to conventional plasmid DNA immunization. Moreover, the effect was not simply owing to the activation of innate immunity, as i.v. administration of non-coding LDC was not effective in controlling tumor growth.
Another set of experiments was conducted to extend these findings to a different tumor model in a different strain of mice. For these studies, the CT26 colon carcinoma model was studied in BALB/c mice. A CT26 tumor line expressing the b-galactosidase (b-gal) gene (CL25) was utilized to facilitate the immunization experiments and mice were immunized with a plasmid expressing the b-gal antigen. The same treatment and control groups and treatment schedules were utilized as described above, except that mice were immunized with b-gal plasmid DNA. CL25 tumors were established in the skin and allowed to grow for 12 days (until tumors were palpable) before immunizations were initiated. I.v. immunization with b-gal LDC significantly (Po0.001) inhibited tumor growth compared to control mice or to mice immunized with b-gal DNA by the i.d. or i.m. routes ( Figure 3 ). In addition, immunization with b-gal LDC was also significantly more effective (Po0.01) than administration of empty vector LDC. These data therefore confirmed and extended the findings in the B16 tumor model system and underscored the potency of the LDC vaccine approach to eliciting therapeutic antitumor immunity.
Immunization with LDC also increases survival in animals with established lung metastases
The preceding results were investigated further to determine whether reduction in tumor growth rate also correlated with increased survival times in mice with lung tumor metastases. For the lung tumor model, tumor metastases were established by i.v. injection of tumor cells before immunization. First, the effects of immunization on survival of mice with established cutaneous B16-ova tumors were assessed. Mice with cutaneous B16-ova tumors treated with ova LDC survived significantly longer (P ¼ 0.002) than control mice (Figure 4a ). In The effects of DNA immunization on survival times in mice with day 7 established B16-ova lung tumor metastases were assessed next in a more rigorous therapeutic vaccination model. Mice were immunized twice, 1 week apart, and killed when progressive tumor growth became apparent. Mice immunized with ova LDC survived significantly longer (P ¼ 0.002) than untreated control mice (Figure 4b ). Survival times in mice immunized with ova plasmid DNA by the i.d. or i.m. routes were not significantly different from control animals. Consistent with our previous findings in lung tumor studies with i.v. administered LDC, mice treated with LDC containing non-coding DNA survived significantly longer than control animals (P ¼ 0.005). 34 However, Liposome-DNA vaccines for cancer L U'Ren et al survival times in mice immunized with ova LDC were significantly longer than in mice treated with non-coding LDC (P ¼ 0.008), indicative of an antigen-specific response in addition to nonspecific activation of innate immunity. These results provided additional evidence of the therapeutic antitumor efficacy elicited when DNA vaccines were formulated as LDC.
Antitumor activity elicited by immunization with LDC vaccines is mediated by CD8 þ T cells DNA immunization has been shown to elicit both CD4 þ and CD8
þ T-cell responses, and both effector cells may help control tumor growth. In addition, we have found that NK cells are one of the major effectors of antitumor activity elicited by i.v. injection of non-coding LDC. 34 Therefore, cell subset depletion experiments were used to assess the relative roles of T cells and NK cells in mediating the antitumor activity elicited by immunization with LDC. B16-ova tumors were established in the skin of C57Bl6 mice (five mice per group) for 7 days, then the mice were depleted of CD4 þ or CD8 þ T cells or NK cells and then immunized with ova-LDC. Controls included non-immunized mice, mice immunized with LDC but not depleted and mice treated with an irrelevant (nondepleting) rat IgG and then immunized. The effects of cell depletion were assessed by measuring tumor growth kinetics ( Figure 5 ). We found that depletion of CD8 þ T cells, but not CD4 þ T cells or NK cells, significantly inhibited the antitumor activity elicited by immunization with ova-LDC. For example, tumor growth was still slowed significantly (Po0.001) following immunization of mice depleted of CD4 þ T cells or NK cells. In contrast, tumor size was not significantly different (P40.05) from tumors in control mice on days 12 and 18 in mice depleted of CD8 þ T cells. These results suggested therefore that the majority of the antitumor effect elicited by immunization with LDC was mediated by CD8 þ T cells.
Uptake of LDC by macrophages and DC in the spleen
Experiments were carried out next to investigate the interaction of LDC with APCs to better understand the ability of LDC to efficiently generate CD8 þ T-cell responses. In the first set of experiments, liposomes labeled with a fluorescent dye (BODIPY, Molecular Probes) were used to track uptake of LDC by splenic APC. At various time points after i.v. administration of labeled LDC, spleen cells were collected from C57Bl6 mice (four mice per group), immunostained with antibodies to relevant cell surface determinants on APCs, then analyzed by multi-color flow cytometry. Panels of antibodies were selected to identify macrophages (CD11b
, and CD4 þ and CD8 þ T cells. Experiments were also carried out to assess the effects of LDC administration on induction of cytokine production directly in vivo, as well as to assess the effects of LDC on activation and upregulation of co-stimulatory molecules on APCs.
One hour after i.v. injection of BODIPY-labeled LDC, the majority of labeled LDC kin the spleen were found in macrophages, neutrophils and DC ( Figure 6 ). Significantly, fewer NK cells (Figure 6b ) or T cells (data not shown) contained labeled LDC. When the kinetics of uptake of LDC were examined, high levels of uptake of labeled LDC were detectable at 1 and 4 h after injection, but by 24 h post-injection, the number of labeled LDC in cells had declined significantly (data not shown). The disappearance of the complexes most likely reflected processing and degradation of the complexes within the APC, although it could not be excluded that the BODIPY label itself was being selectively degraded following binding and internalization of the LDC. Thus, uptake of the LDC appeared to be specifically targeted to key APC in the spleen, including macrophages and DC.
LDC elicit NK cell production of IFN-g and DC production of IL-12 We next assessed the functional effects of LDC on splenic APCs. I.v. administration of LDC has been shown previously to elicit systemic production of proinflammatory cytokines, yet the cellular origin of these cytokines has not been previously identified in vivo. 34 Therefore, ). An additional group of mice was treated with an irrelevant rat IgG and vaccinated (not shown). Tumor growth rates were measured every 2-3 days and the mean tumor diameter (7s.e.) for each treatment group was plotted. Statistical comparison of tumor diameters was carried out using ANOVA. The mean tumor diameter for all groups of vaccinated mice, except the CD8-depleted mice were significantly different (Po0.05) than control mice for days 12, 15 and 18. In the case of CD8-depleted mice, tumor diameters were not significantly different on days 12 and 18 when compared to control mice. Similar results were obtained in one additional experiment.
Liposome-DNA vaccines for cancer L U'Ren et al intracellular cytokine staining was used to identify the cells producing two key cytokines (IL-12 and IFN-g) that are largely responsible for generating Th1-polarized T-cell responses. I.v. administration of LDC was found to elicit production of very high levels of IFN-g by splenic NK cells (Figure 7a and b) . For example, nearly 45% of all NK cells in the spleen were positive for intracellular IFN-g at the peak of the immune response following LDC injection. Production of IFN-g peaked between 4 and 24 h after administration of LDC. Moreover, it appeared that NK cells were the major source of IFN-g production in the spleen, as very little intracellular IFN-g was detected in T cells, DC or macrophages following injection of LDC (data not shown).
Intracellular cytokine staining for IL-12 production revealed that splenic DC were the major cell type responsible for producing IL-12 in the spleen following injection of LDC (Figure 7c) . Production of IL-12 was detectable as soon as 1 h after injection of LDC, then peaked at 4 h and declined thereafter (although not to baseline) by 24 h after injection. At the peak of IL-12 production, approximately 3% of all splenic DC were producing IL-12. In addition, it appeared that DC were the only cells in the spleen capable of producing IL-12 in response to LDC, as intracellular IL-12 was not detected in other cell types (data not shown). These data indicate, therefore, that injection of LDC elicited selective production of IL-12 and IFN-g in vivo and that the cytokine response on a per cell basis was quite robust.
LDC injection triggers upregulation of co-stimulatory molecules on APCs Finally, the effects of LDC on expression of the key co-stimulatory molecule CD86 by APC in the spleen were assessed. Twenty-four hours after injection of LDC, significant upregulation of CD86 expression on both macrophages and DC in the spleen was noted (Figure 7d ). This response was maximal by 24 h after injection of LDC, and also occurred on other cell types including B cells (data not shown). In addition, injection of LDC also elicited upregulation of CD40 expression by APCs in the spleen (data not shown). Taken together, these data indicate that LDC have a marked stimulatory effect on APCs, triggering not only cytokine release but also upregulation of co-stimulatory molecules. In contrast, we did not observe evidence of systemic immune activation in mice injected with plasmid DNA only by the i.d. or i.m. routes (data not shown). Thus, it is likely that strong activation of APCs and robust cytokine release accounts for the efficient induction of functionally active T cells by immunization with LDC.
Discussion
The results of the studies reported here indicate that immunization with LDC is an effective means of generating therapeutic antitumor immunity with plasmid DNA. The enhanced antitumor activity elicited by LDC immunization relative to immunization with conventional plasmid DNA vaccines was mediated in part by the generation of CD8 þ T cells with increased functional activity. The additional nonspecific antitumor effects elicited by activation of innate immunity with LDC probably also contributed to the overall antitumor activity observed. Studies of LDC targeting indicated that LDC were selectively taken up by splenic DC and macrophages, which may explain in part the unique ability of LDC to generate CD8 þ T-cell responses. The efficacy of DNA vaccines depends in part on the inherent immunogenicity of bacterial DNA and its ability to trigger elaboration of local Th1 cytokine responses. 33, 47, 48 Therefore, increasing the inherent immunogenicity of plasmid DNA by complexing to cationic liposomes would be expected to increase potentially the overall effectiveness of a DNA vaccine. Therefore, we reasoned that LDC might serve as a more efficient means of delivering DNA vaccines for cancer. There is precedent for using liposomes to increase the efficacy of DNA vaccines. For example, liposomes have been shown Liposome-DNA vaccines for cancer L U'Ren et al previously to increase the effectiveness of DNA vaccines for mucosal immunization. [49] [50] [51] [52] [53] However, in the previous studies, the liposome-DNA vaccines were administered by conventional routes. In the studies reported here, the major advance is that the vaccines were administered by the i.v. route to take advantage of the strong induction of systemic innate immunity that occurs following i.v. delivery of LDC (for example, see Figure 7 ). 34 The other potential advantage of i.v. administration of LDC is that this route probably also results in more efficient uptake of DNA by DC in the spleen (e.g., Figure 6 ). In addition, cationic liposomes are known to promote endosomal targeting of plasmid DNA, thereby increasing the efficiency of activation of TLR9 and thereby promoting MHC class I-restricted antigen presentation. [54] [55] [56] The systemic immunological responses triggered by i.v. administration of LDC may also synergize with T-cell responses to augment antitumor activity. For example, the strong release of type I and II IFNs triggered by LDC may have direct antitumor effects. 35 In addition, both type I and II IFNs are also potent inhibitors of tumor angiogenesis. Recently, we have shown that LDC are capable of inhibiting tumor angiogenesis in vivo in a large animal spontaneous tumor model. 57 Release of IFNs may therefore render tumor cells more susceptible to attack by CD8 þ T cells. In summary, our findings indicate that LDC administered i.v. may be a particularly efficient means of generating therapeutic antitumor immunity. Such an approach could be considered for patients whose tumors express tumor antigens that are known CD8 þ T-cell targets, including melanoma, renal cell carcinoma, prostate cancer and colon cancer. However, it is also known that LDC injected systemically are capable of triggering toxicity owing to massive activation of innate immune responses. 34, 36 Therefore, for such an approach to be applied clinically, additional studies will have to be carried out to optimize the balance between induction of T-cell-mediated antitumor immunity by LDC vaccines and induction of toxicity by overstimulation of innate immune responses. Liposome-DNA vaccines for cancer L U'Ren et al
